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Abstract: Chromatin remodeling alters gene expression in carcinoma tissue. Although cervical
cancer is the fourth most common cancer in women worldwide, a systematic study about the
prognostic value of specific changes in the chromatin structure, such as histone acetylation or histone
methylation, is missing. In this study, the expression of histone H3 acetyl K9, which is known to
denote active regions at enhancers and promoters, and histone H3 tri methyl K4, which preferentially
identifies active gene promoters, were examined as both show high metastatic potential. A panel of
patients with cervical cancer was selected and the importance of the histone modifications concerning
survival-time (overall survival and relapse-free survival) was analyzed in 250 cases. Histone H3 acetyl
K9 staining was correlated with low grading, low FIGO (TNM classification and the International
Federation of Gynecology and Obstetrics) status, negative N-status and low T-status in cervical cancer,
showing a higher expression in adenocarcinoma than in squamous cell carcinoma. Cytoplasmic
expression of histone H3 tri methyl K4 in a cervical cancer specimen was correlated with advanced
T-status and poor prognosis. While cytoplasmic H3K4me3 expression seemed to be a marker of
relapse-free survival, nuclear expression showed a correlation to poor prognosis in overall survival.
Within this study, we analyzed the chemical modification of two histone proteins that are connected
to active gene expression. Histone H3 acetyl K9 was found to be an independent marker of overall
survival. Histone H3 tri methyl K4 was correlated with poor prognosis and it was found to be an
independent marker of relapse-free survival. Therefore, we could show that chromatin remodeling
plays an important role in cervical cancer biology.
Keywords: cervical cancer; histone H3 acetyl K9; histone H3 tri methyl K4; epigenetics; chromatin
modification; histone proteins; prognosis
1. Introduction
Cervical cancer is the fourth most frequent cancer in women worldwide (about 530,000 new
cases in 2012, 7.5% of all female cancer deaths). The leading cause of cervical cancer is a persistent
infection with high-risk human papillomavirus (HR-HPV) [1]. Specifically, the HPV subtypes 16 and
18 cause about 70% of all cancer cases [1,2]. A total of 170 HPV-types have been described currently [3].
The infection with 15 types of HPV most likely leads to cancer, which is why these 15 types are called
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carcinogenic or high-risk types [4]. The genome of human papillomaviruses consists of approximately
8000 base pairs and contains six “early genes” (E6, E7, E1, E2, E4, E5) and two “late genes” (L1, L2) [5].
In case of replication of the viral gene E6, the E6 oncoprotein is expressed, which disturbs the cell
cycle [6]. E6 oncoprotein and E6-associated protein (E6-AP) form a complex which binds to p53 and
causes its proteolytic degradation [7].
During the different stages of cervical cancer development, there is an accumulation of epigenetic
alterations that leads to changes in gene expression [8]. Altered mechanisms of epigenetic regulation in
cervical cancer include DNA methylation and post-translational modifications of histone proteins [8].
It has been reported that histone modifying enzymes such as histone deacetylase (HDAC)-1 and
HDAC2 are over-expressed in cervical dysplasia and invasive carcinoma [9]. These results suggest
that the dysregulation of enzymes that modify histones in cervical cancer are of importance for the
biology of this tumor entity.
HR-HPVs establish persistent infection by maintaining their genomes as extrachromosomal
elements—the so-called episome—that replicate, together with host DNA, in infected cells [10].
By associating with the host chromatin, HR-HPV redirects the normal cellular control of chromatin
to create a cellular environment that is beneficial for both the HR-HPV multiplication and malignant
progression of the infected cell. Therefore, the investigation of HPV–host chromatin interaction
will offer new insights into the importance of HPV-driven chromatin regulation in cervical cancer
tissue [10].
The state of histone modifications that are connected to the early and late HPV viral
promoters—modification by acetylation and methylation—were examined in a previous study in cell
culture systems using chromatin immunoprecipitation assays: in undifferentiated cells, di-methylated
forms of histone H3K4 as well as acetylated histone H3 and H4 were found [11]. Together with
differentiation, the levels of di-methylated H3K4 and acetylated H3 are increased, while the acetylated
H4 is also increased, which suggests that nucleosomes are activated through histone modifications to
coordinate the HPV transcription during cell differentiation [11].
The already-mentioned studies and several other studies showed that histone protein
modifications play a fundamental role in HPV driven oncogenesis. Because a systematic investigation
of posttranslational changes in histone proteins, for their prognostic relevance in cervical cancer tissue,
was lacking, the aim of this study was an expression analyses of histone H3 acetyl K9 (H3K9ac) and
histone H3 tri methyl K4 (H3K4me3) in cervical cancer, examined in 250 cases by immunohistochemical
methods and assessed by a semi-quantitative score.
2. Results
2.1. H3K9ac Staining in Cervical Carcinoma
To control the quality of our H3K9ac staining, we used normal (non-pathological) colon tissue,
which showed strong nuclear expression in >80% of epithelial cells without a cytoplasmic expression
(Figure 1A).
A total of 92.8% of all cervical cancer specimens showed only a nuclear expression of H3K9ac
with a median Immune Reactive Score (IRS) of 4 (36%), while 7.2% of all samples did not express
H3K9ac at all. Compared to 50.8% with low expression (IRS = 1–5), an enhanced staining (IRS ≥ 6)
was detected in 42.0% of samples.
In the following analyses, we examined the correlation between H3K9ac and several
clinic pathological parameters such as histological subtype, grading, T-status, N-status and
FIGO-classification by noticing the distribution of these parameters in our study group (Table 1).
Int. J. Mol. Sci. 2017, 18, 477 3 of 14
Table 1. Clinic pathological variables of the patients included in this study.
Item No./Total No. %
Age, years
<49 139/250 55.6
>49 111/250 44.4
Number of Positive Nodes
0 151/250 60.4
≥1 97/250 38.8
Not available (NA’s) 2/250 0.8
Tumor Size, pT
pT1 110250 44
pT2/3/4 137/250 54.8
Not available (NA’s) 3/250 1.2
FIGO
I 64/250 25.6
II/III/IV 92/250 36.8
Not available (NA’s) 94/250 37.6
Tumor Grade
I 21/250 8.4
II 143/250 57.2
III 78/250 31.2
Not available (NA’s) 8/250 3.2
Tumor Subtype
Squamous 202/250 80.8
Adenocarcinoma 48/250 19.2
Progression (over 235 months)
None 210/250 84
At least one 21/250 11.6
Not available (NA’s) 11/250 4.4
Survival (over 235 months)
Right censured 190/250 76
Died 49/250 19.6
Not available (NA’s) 11/250 4.4
Examining the histological subtype, squamous epithelial carcinomas (Figure 1B) with a median
IRS of 4 showed a lower H3K9ac expression than adenocarcinoma tissue (Figure 1C) with a median
IRS of 8, differing significantly from each other (p = 0.013; Figure 1D; Table 2).
Regarding the grading, low graded (G1) specimens did not show the general median IRS of 4
in the H3K9ac staining. They presented a median IRS of 8 in 31% of samples (Figure 1E), while the
median IRS of 4 in intermediate graded (G2) and high graded (G3, Figure 1F) samples was represented
by 35.0% and 41.0%, respectively. Thus, enhanced staining was highly significantly correlated with
low grading (p = 0.004; Rho = −0.209 with p = 0.001; Figure 1G and Table 2).
Analysing the N-Status (involved lymph nodes), 86.1% of all patients without lymph-node
metastasis (N−; Figure 1H) had an IRS of ≥4 compared to 66.0% of all patients with lymph-node
positive status (N+; Figure 1I), while both presented the same median IRS of 4 (Figure 1K). An enhanced
expression of H3K9ac was accompanied by lymph node-negative status, while low expression was
accompanied by lymph node-positive status (p = 0.001; Rho = −0.236 with p < 0.001; Table 2).
All tumor sizes (T-stages) showed an equal IRS of 4 (Figure 1L), being represented in 34/110 cases
(31.0%) in T1-stage patients, and 56/137 cases (40.9%) in T2/3/4-stage patients. Data showed a
significant difference (p = 0.035) with an inversed correlation meaning that enhanced H3K9ac staining
correlated with low T-Status (Rho = −0.149 with p = 0.019; Table 2). Although the correlation was
highly significant, it was not detectable in the boxplot.
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Regarding the FIGO status, patients with FIGO I had a median IRS of 8 in 17 patients in this
subgroup (17/64; 26.6%), compared to patients with a FIGO status of II or more with a median IRS of
4 (32/92; 34.8%). We could show a significant correlation between FIGO status and H3acet expression
(p = 0.016) with a negative spearman’s-rank correlation (Rho = −0.192; p = 0.016), meaning that strong
H3K9ac staining correlated with low FIGO status (Figure 1M).
In summary, we detected associations of H3K9ac regarding histological subtype (p = 0.013),
grading (p = 0.004), N-status (p = 0.001), T-status (p = 0.035) and FIGO status (p = 0.016) by using
non-parametric tests (Table 2). In particular, the negative correlation between H3acet staining on the
one hand and FIGO, T- and N-status on the other hand seem to go well together, as FIGO status is
defined by T and N-status.
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Grading: G1-stage tumors showed enhanced H3K9ac expression (E), G3-stage tumors (F) showed 
weak staining; the summary regarding grading is shown as a box plot (G). N-status: Negative 
N-status with high H3K9ac expression (H), positive N-status with low H3K9ac expression (I); the 
summary regarding N-status is shown as a box plot (K). T-status: The median Immune Reactive 
Score (IRS) is 4 for every T-status (L), although there is a strong correlation. TNM classification and 
the International Federation of Gynecology and Obstetrics (FIGO): Boxplot shows a different median 
IRS for FIGO-states (M). Scale bar 200 µm, small pictures 100 µm. 
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Of all the cervical cancer specimens, a total of 96.8% showed H3K4me3 expression, while 3.2% 
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correlating significantly with each other (Rho = 0.290 with p < 0.001). All positive tested samples 
presented a nuclear expression with a median IRS of 8 (31%) compared to a median IRS of 0 (56.4%) 
in samples with cytoplasmic expression (Figure 2B). All in all, nuclear expression of H3K4me3 was 
detectable in 96.8% (negative: 3.2%) of patients, while cytoplasmic expression was only positive in 
43.6% of all patients negative: 56.4%). Nuclear H3K4me3 expression was enhanced (IRS = 4–12) in 
88.4% of all cases compared to a low expression (IRS = 0–3) in 11.6%. Regarding cytoplasmic 
expression, 36.8% slides showed a high expression (IRS = 4–12) and 63.2% slides presented a weak 
expression (IRS = 0–3). 
Examining the T-stage, T1-stage carcinoma tissues showed the general median of 0 in 30.4% of 
all cases in the cytoplasmic H3K4me3 staining (Figure 2C). In contrast, T2/3/4-stage samples showed 
an enhanced median IRS of 2 (Figure 2D) in 3.6% of all cases. Performing nonparametric-tests and 
Spearman’s rank correlation, enhanced cytoplasmic expression of H3K4me3 was correlated with 
advanced T-Status (p = 0.002; Rho = 0.191 with p = 0.003; Table 2). This means that an advanced 
cytoplasmic H3K4me3 expression correlated with higher T-status (Figure 2E). 
In summary, we found associations of cytoplasmic H3K4me3 expression regarding T-status (p = 
0.002) by using non-parametric tests (Table 2). No significant difference was found for cytoplasmic 
expression among N-Status, FIGO or grading and there were no correlations detected between 
nuclear H3K4me3 expression and the described pathological parameters. 
Figure 1. Positive control of H3K9ac staining in colon tissue with strong nuclear cytoplasmic expression
and without cytoplasmic expression in epithelial cells (A). Squamous epithelial tissue (B) showed a
median expression of H3K9ac, while adenocarcinoma tissue (C) showed significantly more intense
H3K9ac staining; the summary regarding histological subtype is shown as a box plot (D). Grading:
G1-stage tumors showed enhanced H3K9ac expression (E), G3-stage tumors (F) showed weak staining;
the summary regarding grading is shown as a box plot (G). N-status: Negative N-status with high
H3K9ac expression (H), positive N-status with low H3K9ac expression (I); the summary regarding
N-status is shown as a box plot (K). T-status: The median Immune Reactive Score (IRS) is 4 for every
T-status (L), although there is strong correlation. TNM classification and the International Feder tion
of Gynecology and Obstetrics (FIGO): Boxplot shows a different median IRS for FIGO-states (M).
Scale bar 200 µm, small pictures 100 µm.
2.2. H3K4me3 Staining in Cervical Cancer
To evaluate the H3K4me3 staining, we used placenta tissue where a very strong expression in
trophoblastic cells, in the nucleus as well as in the cytoplasm, was found (Figure 2A).
Of all the cervical cancer specimens, a total of 96.8% showed H3K4me3 expression, while 3.2%
did not show any expression at all. H3K4me3 was found in the cytoplasm as well as in the nucleus,
correlating significantly with each other (Rho = 0.290 with p < 0.001). All positive tested samples
presented a nuclear expression with a med an IRS of 8 (31%) compared to a median IRS f 0 (56.4%)
in samples with cytoplasmic expr ssion (Figure 2B). All in all, nuclear expres io of H3K4me3 was
detectable in 96.8% (negative: 3.2%) of pati nts, while cytopla mic expression was only positive in
43.6% of all patients negative: 56.4%). Nuclear H3K4me3 expression was enhanced (IRS = 4–12) in
88.4% of all cases compared to a low expression (IRS = 0–3) in 11.6%. Regarding cytoplasmic expression,
36.8% slides showed a high expression (IRS = 4–12) and 63.2% slides presented a weak expression
(IRS = 0–3).
Examining the T-stage, T1-stage carcinoma tissues showed the general median of 0 in 30.4% of all
cases in the cytoplasmic H3K4me3 staining (Figure 2C). In contrast, T2/3/4-stage samples showed
an enhanced median IRS of 2 (Figure 2D) in 3.6% of all cases. Performing nonparametric-tests and
Spearman’s rank correlation, enhanced cytoplasmic expression of H3K4me3 was correlated with
advanced T-Status (p = 0.002; Rho = 0.191 with p = 0.003; Table 2). This means that an advanced
cytoplasmic H3K4me3 xpression correlated with higher T-status (Figu 2E).
In summary, we found association of cytoplasmi H3K4me3 expression regarding T-status
(p = 0.002) by using non-parametric tests (Table 2). No significant difference was found for cytoplasmic
expression among N-Status, FIGO or grading and there were no correlations detected between nuclear
H3K4me3 expression and the described pathological parameters.
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Table 2. Staining results and correlation analysis.
H3K9ac H3K4me3 (Cytoplasmic) H3K4me3 (Nuclear)
Median IRS
(+/−SD) % p (NPAR) ρ
Median IRS
(+/−SD) % p (NPAR) ρ
Median IRS
(+/−SD) % p (NPAR) ρ
Histology
SCC 4 (+/−3.45) 40.10%
0.013 -
0 (+/−2.67) 57.40%
0.296 -
8 (+/−3.56) 32.20%
0.603 -Adeno-Ca 8 (+/−3.78) 31.30% 0 (+/−3.35) 52.10% 8 (+/−3.58) 27.10%
Grade
G1 8 (+/−3.51) 31.00%
0.004 −0.209 (p = 0.001)
0 (+/−2.94) 57.10%
0.197 0.082 (p > 0.05)
8 (+/−3.66) 28.60%
0.917 −0.017 (p > 0.05)G2 4 (+/−3.57) 35.00% 0 (+/−3.08) 52.40% 8 (+/−3.59) 31.50%
G3 4 (+/−3.26) 41.00% 0 (+/−2.24) 62.80% 8 (+/−3.55) 33.30%
pN
N− 4 (+/−3.55) 86.10%
0.001 −0.236 (p = 0.000) 0 (+/−3.02) 57.00% 0.981 −0.001 (p > 0.05) 8 (+/−3.50) 32.50% 0.695 0.025 (p > 0.05)N+ 4 (+/−3.33) 66.00% 0 (+/−2.43) 55.70% 8 (+/−3.69) 28.90%
pT
T1 4 (+/−3.52) 30.90%
0.035 −0.149 (p = 0.019) 0 (+/−2.34) 69.10% 0.002 0.191 (p = 0.003) 8 (+/−3.49) 30.00% 0.171 0.081 (p > 0.05)T2/3/4 4 (+/−3.49) 40.90% 2 (+/−2.93) 3.60% 8 (+/−3.60) 32.10%
FIGO
I 8 (+/−3.91) 26.60%
0.016 −0.192 (p = 0.016) 0 (+/−2.45) 64.10% 0.324 0.070 (p = 0.384) 8 (+/−3.37) 32.80% 0.862 −0.005 (p = 0.948)II+ 4 (+/−3.44) 23.90% 2 (+/−2.66) 5.40% 8 (+/−3.67) 30.40%
p16 - - - 0.047 (p > 0.05) - - - 0.009 (p > 0.05) - - - 0.144 (p = 0.027)
SD = standard deviation; % = percentage of the subgroup with median IRS; NPAR = non-parametric test; p = p-value; ρ = correlation coefficient; SCC = squamous cell carcinoma,
pT = tumor size, FIGO = TNM classification and the International Federation of Gynecology and Obstetrics.
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2.3. Correlation Analysis between H3K4me3 and p16 Oncoprotein
It is well known that the expression of p16 oncoprotein in cancer is not only associated with
DNA methylation but also with histone modification [12]. By using recently published data by our
institute [13,14], we looked for a similar association in cervical cancer. Analyses showed that a nuclear
H3K4me3 expression was positively correlated with p16 expression (Rho = 0.144; p = 0.027; Table 2).
No correlation was found regarding the cytoplasmic expression of H3K4me3 (Rho = 0.009; p > 0.05) or
nuclear H3K9ac expression (Rho = 0.047; p > 0.05).
. .
H3K9ac expres ion (IRS ≥ 6) was—as well as H3K4me3 expr ssion (IRS ≥ 4)—
associated with survival-time aft r diagnosis.
s shown in the Kaplan–Meier curve (Figure 3A), high expression of H3K9ac (IRS ≥ 6) in cervical
ancer patients was correl ted with poor prognosis in overall survival rates (p = 0.027). This was in
contrast t the correlation betwee H3K9ac staining and the described clini pathological parameters
(T-status, N-status, Grading and FIGO), where high H3K9ac expression was correlated with the low
stage of these p rameters.
I a iti t , i t l f f r s r i l, f
si il r c rrel ti : l l t it r sis
cerning overall survival (Figure 3B, p = 0. 66). For cytoplasmic H3K4me3 xpression, there was no
significan e con erning overall survival.
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Figure 3. Kaplan–Meier analyses for overall survival: H3K9ac (p = 0.027; A) with high expression
(IRS ≥ 6; red) compared to low expression (IRS ≤ 5; black); High nuclear H3K4me3 expression
(IRS ≥ 4; red) compared to low expression (IRS ≤ 3; black) regarding overall survival (p = 0.066; B).
2.5. Role of H3K9ac and H3K4me3 for Progress-Free Survival
Although H3K9ac and nuclear H3K4me3 expressions showed significant differences regarding
overall survival, their expressions showed no significant correlation for relapse-free survival (p = 0.763
and p = 0.08).
In contrast, cytoplasmic H3K4me3 expression, which was not a marker of overall survival,
was significantly correlated with progress-free survival: high cytoplasmic expression of H3K4me3
(IRS ≥ 4) meant short relapse-free survival (Figure 4, p = 0.025), matching the correlation between high
expression and advanced T-Status.
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2.6. Cox Regression of H3K9ac a d H3K4me3 and Clinic Pathological Variables
The additionally performed multivariate cox-regression tested which histopathological
parameters were independent prognosticators for survival in our study-group.
For overall survival, the histological subtype (p = 0.040), pN-status (p = 0.003), FIGO classification
(p = 0.012), age at surgery (p < 0.001) and the expr ssion of H3K9ac (p = 0.027) were independent
prognosticators, but not the H3MK4me3 expression or other tested clinic pathological parameters
(Table 3).
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Regarding relapse-free survival, only FIGO status (p = 0.044) and cytoplasmic H3K4me3
expression (p = 0.030) turned out to be independent markers in multivariate cox-analysis (Table 4),
but not H3K9ac expression, nuclear H3K4me3 expression or other described parameters.
Table 3. Cox regression of clinic pathological variables regarding overall survival.
Variable Significance Hazard Ratio of Exp(B) Lower 95% CI of Exp(B) Upper 95% CI of Exp(B)
Histology 0.040 1.893 1.030 3.479
pT 0.751 0.910 0.509 1.626
pN 0.003 2.447 1.367 4.380
FIGO 0.012 3.181 1.287 7.863
Grading 0.198 1.360 0.852 2.170
Age at surgery 0.000 1.049 1.026 1.072
H3K9ac 0.027 1.900 1.076 3.356
H3K4me3 nucleus 0.708 1.216 0.436 3.389
H3K4me3 cytoplasm 0.159 1.503 0.853 2.651
Table 4. Co12x regression of clinic pathological variables regarding progress-free survival.
Variable Significance Hazard Ratio of Exp(B) Lower 95% CI of Exp(B) Upper 95% CI of Exp(B)
Histology 0.753 1.156 0.469 2.851
pT 0.760 0.890 0.423 1.875
pN 0.843 1.082 0.495 2.368
FIGO 0.044 3.085 1.031 9.235
Grading 0.521 1.228 0.656 2.299
Age at surgery 0.157 1.021 0.992 1.052
H3K9ac 0.763 0.890 0.417 1.900
H3K4me3 nucleus 0.476 0.681 0.236 1.963
H3K4me3 cytoplasm 0.030 2.278 1.084 4.790
3. Discussion
Within this study, we showed that the immunohistochemical evaluation of histone H3K9ac
staining was correlated with low grading, low FIGO-classification, low T-status and negative N-status
in cervical cancer. We could also find a higher expression of histone H3K9ac in adenocarcinoma
compared to squamous cell carcinoma. Due to its correlation between expression and poor prognosis
(overall survival), it could be used as an independent marker of prognosis. Cytoplasmic expression
of histone H3K4me3 in a cervical cancer specimen was correlated with advanced T-status and poor
prognosis. It seems to be a marker of relapse-free survival, while nuclear expression showed a
correlation to poor prognosis without being an independent marker regarding cervical cancer.
Histone proteins give the genome the ability to pack very large amounts of DNA in a very
small space, but at the same time they leave their N-terminal tails flexible [15]. The N-terminal tail
of the histone proteins can undergo post-translational modification by enzymes, adding chemical
modifications such as acetylation, methylation, phosphorylation and deamination that alter the
structure of the DNA package and allow or prevent gene transcription [16]. It is already known
that histone modifications at histone 3 lysine 9 acetylation (H3K9ac) denote active regions at enhancers
as well as promoters, whereas the tri-methyl form, H3K4me3, preferentially identifies the gene
promoters that are active [17,18]. In addition, it has been shown that epigenetic modulations of the
genome involve histone modifications that alter the gene chromatin configuration. A decondensed
(“open”) configuration allows transcription factors access to binding sites, whereas a condensed
(“closed”) configuration blocks transcription binding sites, thereby regulating gene transcription [19,20].
Based on these findings, it has been shown that high metastatic potential had greater acetylation of
histone H3 lysine 9 (H3K9ac) and tri-methylation of histone H3 lysine 4 (H3K4me3) [19]. Therefore,
these two modifications that are correlated to enhanced gene activity and in addition show high
metastatic potential were used in the present study as markers for the identification of the prognostic
relevance of those histone modifications for cervical cancer survival.
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It is already known that E6 oncoprotein and E6-associated protein (E6-AP) form a complex which
binds to p53 and causes its proteolytic degradation [7]. P53 is a tumor suppressor, as it leads to cell
cycle arrest or apoptosis in the case of DNA damage [21]. As E6 oncoprotein induces the degradation of
p53, the function of this important cell cycle protein is disturbed [12] after HPV infection. The cell cycle
regulation protein p16 is expressed at high levels in HPV-infected epithelial cells, which is why it acts
as a marker for the diagnosis of a HPV associated carcinoma [22,23]. On the other hand, studies have
shown that p16 expression is induced by an oncogene senescence-related mechanism that involves
histone H3K27 demethylation by histone lysine demethylase, and that p16 expression is necessary for
the survival of HPV-infected cells expressing E7 viral oncoprotein [24,25].
Unfortunately, p16 is not exclusively increased by E7 oncoprotein in carcinogenesis. Therefore,
in a recent study, we established and published an immunohistochemical approach for the direct
detection of E6 oncoprotein in uterine cervical cancer [14]. In addition, we found a very high mutation
rate of TP53 in this cancer type where p53 is initially inactivated via E6 during the development of
cervical cancer. An unexpected finding is the correlation of this mutation with better survival, possibly
due to better response to therapy [13].
Because both H3K9ac and H3K4me3 are negative prognosticators for cervical cancer patients,
the use of epigenetic drugs or the search for epigenetic targets could be a useful goal for cervical
cancer treatment.
Recently, two main classes of epigenetic drugs—methylation inhibitors and HDAC inhibitors—are
in clinical trials for the treatment of cervical cancer [26]. One of these potential new drugs could be
valproic acid (VPA). VPA was found to be an effective inhibitor of histone deacetylases and has
been shown to induce anti-tumor effects by modulating cellular pathways, including cell cycle arrest,
apoptosis, angiogenesis, metastasis, differentiation, and senescence [27]. The antitumor effect of VPA
in cervical cancer can be explained by either the hyper-acetylation of p53 protein, protecting it from
degradation by E6 and increasing p53 activity; or via the inhibition of Akt1 and Akt2 expression,
which results in apoptotic cell death [28,29]. Acetylation of p53 is a process that occurs in response to
DNA damage and stress and is necessary for p53 transcriptional activity. Therefore, p53 was one of the
first non-histone proteins that could be acetylated by histone acetyl transferases [30].
In addition, HDAC inhibitors also interfere with cervical cancer via non-histone targets.
The HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) induces apoptosis in HeLa cervical
cancer cells in vitro with bortezomib by activating caspase-3 and increasing the ratio of bax/bcl-2
expression [31]. Epigenetic aberrations, such as histone protein modification have the ability to
regulate the expression of oncogenes or repression of tumor suppressor genes. Therefore, these
modified histone proteins are powerful candidates for the investigation of cancer pathogenesis and
progression. For cervical cancer, for instance, Feng et al. [26] highlighted a number of genes that
underwent epigenetic alteration at the level of DNA methylation, histone modification, or noncoding
RNA action in this type of cancer.
Further investigation of these alterations and information about them could lead to new and
reliable screening methods for women at high risk of cervical cancer and can help to establish new
candidates for a better treatment of this disease.
4. Materials and Methods
4.1. Patients and Specimens
We used 250 paraffin-embedded cervical cancer samples obtained from patients having
undergone surgery for cervical cancer in the Department of Obstetrics and Gynecology of the
Ludwig-Maximilians-University of Munich between 1993 and 2002. The median age of the patients
was 47.0 years (range 20–83 years), and overall median survival was 100.0 months. For distribution
of clinic pathological variables see Table 1. Only patients with adenocarcinoma or squamous cell
carcinoma (SCC) of the cervix were included in our study, other histological subtypes were excluded
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due to low number. As positive controls for immunohistochemically staining, we utilized colon tissue
for histone H3 acetyl K9 and placenta tissue for histone H3 tri methyl K4; both received from the
Department of Obstetrics and Gynecology of the Ludwig-Maximilians-University of Munich. Clinical
and follow-up data for statistical analyses were provided by the Munich cancer registry and retrieved
from medical records.
4.2. Ethics Approval
All cervical cancer specimens had originally been collected for histopathological diagnostics and
were no longer used for clinical tests, when they were recruited for this survey. Patient data were
totally anonymized and the authors were blinded for clinical information—including survival-time
during experimental analyses. The study was conducted conforming to the Declaration of Helsinki
and was approved by the local ethics committee of the Ludwig-Maximilians University of Munich
(reference number 259-16, 2016).
4.3. Immunohistochemistry
The paraffin-embedded and formalin-fixed samples (3 µm) had been stored at room temperature
and were first dewaxed in xylol. After rinsing the tissue in 100% ethanol and blocking the endogenous
peroxidase with 3% methanol/H2O2, the samples were rehydrated in a descending alcohol series.
To avoid heat-associated protein-agglomeration and to unmask the antigen, the slides were warmed
up to 100 ◦C in a pressure cooker for 5 min, adding a trisodium citrate buffer solution with pH = 6.
After having prepared the slides by washing them in distilled water and PBS-buffer, we added the
suitable blocking solution to avoid unspecific (hydrophobic) bindings between immunoglobulins
on the one side and cell membranes or fatty tissue on the other side by saturation of electrostatic
charges. Afterwards, the samples were incubated at a temperature of +4 ◦C with the primary antibodies
(Table 5).
After increasing the staining by the post-block-reagent and applying the HRP-polymer,
the substrate-staining with DAB was performed and the counterstaining by haemalm (2 min) was
carried out subsequently. More details concerning the suitable detection system and the following
steps were defined exactly in Table 5. Finally, the samples were dehydrogenated in a rising alcohol
series and covered. Colon tissue and placenta tissue were used for each staining as positive and
negative controls for H3K9ac and H3K4me3.
The intensity of the expression was evaluated by the immunoreactive score (IRS). Well-established
and applied in numerous other studies, this semi-quantitative score multiplies the intensity of the
staining (0 = not stained; 1 = low intensity; 2 = moderate intensity; 3 = high intensity) and the
percentage of stained cells (0 = 0%; 1 = 1%–10%; 2 = 11%–50%; 3 = 51%–80%; 4 ≥ 80%). Finally,
we distinguished between 0 = no expression and 12 = very high expression of histones.
Table 5. Antibodies and chemicals used for the immunohistochemistry.
Histone H3 Acetyl K9 1 Histone H3 Tri Methyl K4 2
Blocking solution 3: 5 min Blocking solution 3: 5 min
primary antibody 1: 1:200 in PBS 5, incubation: 16 h, 4 ◦C primary antibody 2: 1:500 in PBS 5, incubation: 16 h, 4 ◦C
PostBlock 3: 20 min PostBlock 3: 20 min
HRP Polymer 3: 30 min HRP Polymer 3: 30 min
Chromogen: DAB 4 (0.5 min) Chromogen: DAB 4 (1 min)
1 Anti Histone H3 acetyl K9, clone Y28 (rabbit IgG), concentration: 0.059 mg/mL, company: Abcam (Cambridge,
UK), order number: ab32129; 2 Anti Histone H3 tri methyl K4, rabbit IgG polyclonal, concentration: 1 mg/mL,
company: Abcam, order number: ab8580; 3 ZytoChem Plus HRP Polymer Kit (Mouse/Rabbit) 3 × 100; company:
Zytomed Systems (Berlin, Germany) Nr. POLHRP-100; 4 Liquid DAB + Substrate Chromogen System 1 mg/mL,
DAKO; 5 Dulbecco’s Phosphate Buffered Saline.
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4.4. Statistics
For statistical analyses, IBM SPSS Statistics version 23 (Armonk, NY, USA) was used. Bivariate
correlations were calculated by Spearman’s-rank-correlation coefficient and non-parametric tests
(NPAR: Mann–Whitney U test, Kruskal–Wallis test) were employed to compare independent groups.
To visualize differences concerning survival rates, Kaplan–Meier curves were created and afterwards
compared by a log-rank test and—if necessary—Mann–Whitney-U test. Survival times are shown in
years, but for more exact results they were calculated in months. To show statistical difference, p had
to be <0.05.
5. Conclusions
The expression of histone H3 acetyl K9 and histone H3 tri methyl K4 was examined in 250 cases
of cervical cancer. Both histone protein modifications turned out to be independent negative
prognosticators for the overall survival or the relapse-free survival of cervical cancer patients.
For cervical cancer, it is the first study that showed a direct link between histone protein modification
and survival in a large cohort of patients.
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